Corcept Therapeutics is a commercial-stage pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders. The company's lead product, Korlym, is a cortisol receptor blocker that modulates the effects of cortisol, a hormone produced by the adrenal gland. Korlym is approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with Cushing's syndrome who have type 2 diabetes or glucose intolerance. The company is also developing other cortisol modulators, including CORT125134, which is in Phase II clinical trials for the treatment of patients with Cushing's syndrome and solid-tumor cancers. Corcept Therapeutics was founded in 1998 and is headquartered in Menlo Park, California.